CN114173826A - 使用脂质纳米颗粒用于递送编码vegf-a多肽的经修饰的rna的方法和包含其的药物组合物 - Google Patents

使用脂质纳米颗粒用于递送编码vegf-a多肽的经修饰的rna的方法和包含其的药物组合物 Download PDF

Info

Publication number
CN114173826A
CN114173826A CN202080046774.1A CN202080046774A CN114173826A CN 114173826 A CN114173826 A CN 114173826A CN 202080046774 A CN202080046774 A CN 202080046774A CN 114173826 A CN114173826 A CN 114173826A
Authority
CN
China
Prior art keywords
glycero
nanoparticle
lipid
peg
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN202080046774.1A
Other languages
English (en)
Chinese (zh)
Inventor
K·M·汉松
M·瓦格贝里
N·博根赫姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ModernaTx Inc
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN114173826A publication Critical patent/CN114173826A/zh
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Nanotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202080046774.1A 2019-05-08 2020-05-08 使用脂质纳米颗粒用于递送编码vegf-a多肽的经修饰的rna的方法和包含其的药物组合物 Withdrawn CN114173826A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962845184P 2019-05-08 2019-05-08
US62/845,184 2019-05-08
PCT/US2020/032241 WO2020227690A1 (en) 2019-05-08 2020-05-08 Methods of using lipid nanoparticles for delivering modified rna encoding a vegf-a polypeptide and pharmaceutical compositions comprising the same

Publications (1)

Publication Number Publication Date
CN114173826A true CN114173826A (zh) 2022-03-11

Family

ID=71069932

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080046774.1A Withdrawn CN114173826A (zh) 2019-05-08 2020-05-08 使用脂质纳米颗粒用于递送编码vegf-a多肽的经修饰的rna的方法和包含其的药物组合物

Country Status (5)

Country Link
US (1) US20220226243A1 (https=)
EP (1) EP3965745A1 (https=)
JP (1) JP2022532075A (https=)
CN (1) CN114173826A (https=)
WO (1) WO2020227690A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114306279A (zh) * 2021-12-30 2022-04-12 复旦大学 基于科罗索酸或其类似物的脂质纳米颗粒系统及其制备方法和应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114617980A (zh) * 2022-03-09 2022-06-14 广州国家实验室 可电离脂质纳米颗粒及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016118725A1 (en) * 2015-01-23 2016-07-28 Moderna Therapeutics, Inc. Lipid nanoparticle compositions
WO2017214175A1 (en) * 2016-06-07 2017-12-14 Modernatx, Inc. Modified rna encoding vegf-a polypeptides, formulations, and uses relating thereto
CN109152735A (zh) * 2016-05-09 2019-01-04 阿斯利康(瑞典)有限公司 包含亲脂性抗炎剂的脂质纳米颗粒及其使用方法
CN111356444A (zh) * 2017-10-31 2020-06-30 摩登纳特斯有限公司 用于递送编码vegf-a多肽的经修饰的rna的脂质纳米颗粒

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6948313B6 (ja) 2015-09-17 2022-01-14 モデルナティエックス インコーポレイテッド 治療剤の細胞内送達のための化合物および組成物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016118725A1 (en) * 2015-01-23 2016-07-28 Moderna Therapeutics, Inc. Lipid nanoparticle compositions
US20180085474A1 (en) * 2015-01-23 2018-03-29 Moderna Therapeutics, Inc. Lipid nanoparticle compositions
CN109152735A (zh) * 2016-05-09 2019-01-04 阿斯利康(瑞典)有限公司 包含亲脂性抗炎剂的脂质纳米颗粒及其使用方法
WO2017214175A1 (en) * 2016-06-07 2017-12-14 Modernatx, Inc. Modified rna encoding vegf-a polypeptides, formulations, and uses relating thereto
CN111356444A (zh) * 2017-10-31 2020-06-30 摩登纳特斯有限公司 用于递送编码vegf-a多肽的经修饰的rna的脂质纳米颗粒

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114306279A (zh) * 2021-12-30 2022-04-12 复旦大学 基于科罗索酸或其类似物的脂质纳米颗粒系统及其制备方法和应用

Also Published As

Publication number Publication date
JP2022532075A (ja) 2022-07-13
WO2020227690A1 (en) 2020-11-12
US20220226243A1 (en) 2022-07-21
EP3965745A1 (en) 2022-03-16

Similar Documents

Publication Publication Date Title
EP3703658B1 (en) Lipid nanoparticles for delivering modified rna encoding a vegf-a polypeptide
JP7275111B2 (ja) 脂質ナノ粒子の生成方法
KR102617833B1 (ko) 인터류킨 17 수용체 mRNA의 특이적 녹다운을 위한 안티센스 올리고뉴클레오티드 (ASO)를 제시하는 리포좀성 구형 핵산 (SNA) 구축물
RU2712511C2 (ru) Миметики mir-29 и пути их применения
JP2023513043A (ja) 脂質ナノ粒子を調製する方法
CN114173826A (zh) 使用脂质纳米颗粒用于递送编码vegf-a多肽的经修饰的rna的方法和包含其的药物组合物
Rajendran et al. Engineered extracellular vesicle mimetics from macrophage promotes hair growth in mice and promotes human hair follicle growth
CA2356701C (en) Gene therapy for diabetic ischemic disease
AU2022240726A1 (en) Copper histidinate compositions and uses thereof
TW202400784A (zh) 包含utr的核酸構建體及其應用
HK40034375B (en) Lipid nanoparticles for delivering modified rna encoding a vegf-a polypeptide
HK40034375A (en) Lipid nanoparticles for delivering modified rna encoding a vegf-a polypeptide
AU2023274159A1 (en) COMPOSITION FOR IN-VIVO DELIVERING mRNA CONTAINING MODIFIED NUCLEOTIDE
WO2024029597A1 (ja) ＩＦＮ－γへ選択的に結合するＤＮＡオリゴヌクレオチドを含有するドライアイ治療薬
EA043705B1 (ru) Липидные наночастицы для доставки модифицированной рнк, кодирующей полипептид vegf-a
CN119080908B (zh) 一种预防或治疗心肌缺血再灌注损伤的多肽及其应用
WO2024197307A1 (en) Peg targeting compounds for delivery of therapeutics
WO2024197310A1 (en) Peg targeting compounds for delivery of therapeutics
CN116440163A (zh) 一种用于哺乳动物骨骼和/或肌肉抗衰的生物制品及其制备方法和应用
WO2025103396A1 (zh) 一种含核酸构建体的药物组合物及其医药用途
CN116440165A (zh) 一种用于哺乳动物皮肤和/或毛囊抗衰的生物制品及其制备方法和应用
CN116440168A (zh) 一种生物制品及其制备方法和其在制备抗衰延寿产品中的应用
FUKUYAMA 7 days to afford cationized gelatin. The conversion rate

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20230515

Address after: Massachusetts

Applicant after: MODERNATX, Inc.

Address before: Swedish Sodertalje

Applicant before: ASTRAZENECA AB

TA01 Transfer of patent application right
WW01 Invention patent application withdrawn after publication

Application publication date: 20220311

WW01 Invention patent application withdrawn after publication